New IO Targets and Resistance Mechanisms of Immune Checkpoint-Based Therapies
At the ASCO 2021 virtual annual meeting, Dr. Antoni Ribas from UCLA, Dr. Patrick Alexander Ott from Dana Farber together with Dr. Kurt A. Schalper from Yale University teamed to discuss resistance mechanisms of checkpoint inhibitors, potential therapeutic combinations, neoantigen landscape, tumor mutational burden, and the role of tumor microenvironment in cancer immunotherapy.
Therapeutic resistance can be of two types, viz, primary resistance- wherein patients generally do not respond to therapy, and acquired resistance- where patients respond initially but still undergo disease progression.
Therapeutic resistance can be of two types, viz, primary resistance- wherein patients generally do not respond to therapy, and acquired resistance- where patients respond initially but still undergo disease progression.
GO Prime with only $1.49 now
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115